Theranostics Approaches To Gastric And Colon Cancer

This book highlights the importance of understanding gastric and colon cancer metabolism in guiding diagnosis and drug discovery. It summarizes the correlation between adiponectin and matrix metalloproteinase with colorectal cancer. The book also evaluates the divergent role of hypoxia-inducible factor 1 in colorectal cancer growth and metastasis. After discussing the role of genetic polymorphisms in alcohol metabolizing enzymes and EPHX1 with the onset of colorectal cancer, it reviews the molecular mechanisms of chemoresistance in gastric cancer and novel therapeutic strategies to reverse the chemoresistance of tumors. In addition, the book explores the theranostic role of nanoparticles and therapeutic potential of phytochemicals with regard to colorectal cancer. Given its scope, the book offers a valuable guide for oncologists, academic researchers, pharmaceuticals practitioners, and students who are involved in research and treatment of cancer.

This book highlights the importance of understanding gastric and colon cancer metabolism in guiding diagnosis and drug discovery. It summarizes the correlation between adiponectin and matrix metalloproteinase with colorectal cancer. The book also evaluates the divergent role of hypoxia-inducible factor 1 in colorectal cancer growth and metastasis. After discussing the role of genetic polymorphisms in alcohol metabolizing enzymes and EPHX1 with the onset of colorectal cancer, it reviews the molecular mechanisms of chemoresistance in gastric cancer and novel therapeutic strategies to reverse the chemoresistance of tumors. In addition, the book explores the theranostic role of nanoparticles and therapeutic potential of phytochemicals with regard to colorectal cancer. Given its scope, the book offers a valuable guide for oncologists, academic researchers, pharmaceuticals practitioners, and students who are involved in research and treatment of cancer. --

The term theranostics is derived from the combination of two words, namely, therapeutics and diagnostics. It is a practical aspect of personalized medicine. It involves using a combination of one radioactive drug to identify (diagnose) and a second radioactive drug to provide therapy in order to treat a tumor. Gastric cancer, also known as stomach cancer, develops due to the formation of malignant cancer cells in the lining of the stomach. The factors such as age, diet, and stomach diseases result in the development of gastric cancer. Some of the common symptoms of this cancer include unexplained weight loss, severe abdominal pain, nausea and vomiting, difficulty in swallowing, etc. It can be diagnosed with the help of imaging tests such as CT or CAT scans, PET scans, MRI, or upper gastrointestinal endoscopy. Theranostics includes molecular targeting and nanotechnologies which are increasingly finding many applications in the treatment of gastric cancer. In this book, the various advancements in the field of theranostics as well as their application for the treatment of gastric cancer have been looked at in detail. For all readers who are interested in this area of study, the case studies included herein will serve as an excellent guide to develop a comprehensive understanding.

This book provides an up-to-date overview of gastrointestinal malignancies, including prevention, early detection, intervention, and life-extending therapeutics. It also assesses various biomarkers used for diagnostics, prognostics and prediction of response to chemoresistance. Further, it discusses the latest trends in the use of small-molecule targeted therapies and immunotherapies as single agents or combination with other treatments. Since resistance to radiation and chemotherapy contribute to the high recurrence and poor survival rates, improving the outcome for GI malignancies is dependent on the introduction of new biomarkers and therapeutic agents. Lastly, the book systematically investigates novel theranostics approaches using nanotechnology for the detection, diagnosis, and personalized treatment of GI malignancies.

This book covers scientific, clinical, and educational aspects of radiotheranostics in cancer control. Setting the framework, the first volume defines radiotheranostics and describes the history of radionuclide therapy and theranostics, and the biology of cancer. It examines the clinical applications of unconjugated radionuclides, such as 131I and 223Ra, and of radionuclide-conjugated cancer-specific vectors: peptides, small molecules, antibodies, and nanoparticles; introduces clinical trials and drug development; and reviews epidemiological studies and the adverse effects of radionuclide therapy – both radiation injuries and chemical toxicity. It presents the chemistry and physics of radionuclide production, discusses radioactivity measurements and traceability, and addresses important instrumentation aspects: calibration, quantitative imaging, and quality control. Volume I concludes with guidance on the education, training, and competence of a radiotheranostic multidisciplinary team and summarizes the principal physics characteristics of theranostics today – including many to be expanded in the second volume – while offering a glimpse into tomorrow. This volume provides the foundations for the more advanced second volume, which explores dosimetric and radiation safety, aiming to empower medical physicists and demonstrate to the cancer community how to improve cancer control and yield increased patient survival times.It will be a valuable reference for medical and health physicists with basic knowledge of nuclear medicine. Key Features Provides a comprehensive introduction to the topic, presenting readers with thorough treatment in a cohesive two-volume book Presents a rigorous approach while remaining accessible to students and trainees in the field Contains consistent and extensive references to allow readers to delve deeper into the subject

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage also addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

The book explores recent developments in the application of nanotechnology in the early detection of gastric cancer. It discusses various aspects, such as screening for gastric cancer-associated biomarkers; establishing new ultrasensitive detection methods based on nanoparticle labeling and nanoeffects; developing a new generation of nanodevices for high-throughput examination of serum and breath biomarkers; developing multifunctional nanoprobes for targeted imaging and simultaneous therapy of gastric cancer; evaluating the biosafety of multifunctional nanoprobes; and the establishment of a pre-warning and early diagnosis system. It also presents clinical applications and prospects. The book provides a valuable reference for researchers in nanomedicine and clinicians involved in gastric cancer and radiology.

Advances in Cancer Research, Volume 139, provides invaluable information on the exciting and fast-moving field of cancer research. Original reviews are presented on a variety of topics relating to the rapidly developing intersection between nanotechnology and cancer research, with unique sections in the new release focusing on Exosomes as a theranostic for lung cancer, Nanotechnology and cancer immunotherapy, Ultrasound imaging agents and delivery systems, Dendronized systems for the delivery of chemotherapeutics, Thermosensitive liposomes for image-guided drug delivery, Supramolecular Chemistry in Tumor Analysis and Drug Delivery, Gold nanoparticles for delivery of cancer therapeutics, and Single cell barcode microchip for cancer research and therapy. Provides the latest information on cancer research Offers outstanding and original reviews on a range of cancer research topics Serves as an indispensable reference for researchers and students alike